Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.05
AMRS's Cash to Debt is ranked lower than
93% of the 1073 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 0.79 vs. AMRS: 0.05 )
Ranked among companies with meaningful Cash to Debt only.
AMRS' s Cash to Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.76 Max: N/A
Current: 0.05
Equity to Asset -1.53
AMRS's Equity to Asset is ranked lower than
99% of the 1038 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 0.53 vs. AMRS: -1.53 )
Ranked among companies with meaningful Equity to Asset only.
AMRS' s Equity to Asset Range Over the Past 10 Years
Min: -1.53  Med: 0.05 Max: 0.87
Current: -1.53
-1.53
0.87
F-Score: 2
Z-Score: -17.81
M-Score: -9.30
WACC vs ROIC
27.92%
-1518.65%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -427.19
AMRS's Operating margin (%) is ranked lower than
98% of the 1054 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 6.31 vs. AMRS: -427.19 )
Ranked among companies with meaningful Operating margin (%) only.
AMRS' s Operating margin (%) Range Over the Past 10 Years
Min: -434.9  Med: -252.28 Max: -98.14
Current: -427.19
-434.9
-98.14
Net-margin (%) -515.84
AMRS's Net-margin (%) is ranked lower than
98% of the 1058 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 4.54 vs. AMRS: -515.84 )
Ranked among companies with meaningful Net-margin (%) only.
AMRS' s Net-margin (%) Range Over the Past 10 Years
Min: -638.16  Med: -200.03 Max: 5.28
Current: -515.84
-638.16
5.28
ROA (%) -129.03
AMRS's ROA (%) is ranked lower than
99% of the 1078 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 3.87 vs. AMRS: -129.03 )
Ranked among companies with meaningful ROA (%) only.
AMRS' s ROA (%) Range Over the Past 10 Years
Min: -133.56  Med: -55.57 Max: 1.1
Current: -129.03
-133.56
1.1
ROC (Joel Greenblatt) (%) -119.57
AMRS's ROC (Joel Greenblatt) (%) is ranked lower than
97% of the 1068 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 12.39 vs. AMRS: -119.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AMRS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -193.95  Med: -146.73 Max: 25.82
Current: -119.57
-193.95
25.82
Revenue Growth (3Y)(%) -40.80
AMRS's Revenue Growth (3Y)(%) is ranked lower than
97% of the 940 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 2.10 vs. AMRS: -40.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AMRS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -52.30 Max: -25.8
Current: -40.8
EBITDA Growth (3Y)(%) -33.60
AMRS's EBITDA Growth (3Y)(%) is ranked lower than
94% of the 829 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 5.70 vs. AMRS: -33.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AMRS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -26.10 Max: 4.7
Current: -33.6
0
4.7
EPS Growth (3Y)(%) -21.50
AMRS's EPS Growth (3Y)(%) is ranked lower than
86% of the 729 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 8.50 vs. AMRS: -21.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AMRS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -24.75 Max: 4.4
Current: -21.5
0
4.4
» AMRS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with AMRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Chemicals » Specialty Chemicals
Compare:NAS:SYMX, NAS:GURE, NAS:SNMX, OTCPK:LPAD, OTCPK:ECSNF, OTCPK:APGMF, NAS:NTIC, NAS:AMTX, OTCPK:DTRX, OTCPK:AXXIY, OTCPK:LWLG, OTCPK:HDGHF, NAS:MBLX, OTCPK:GRPEF, NAS:GEVO, OTCPK:ALLM, NAS:IKNX, OTCPK:DDXFF, NAS:TVIA, OTCPK:NANX » details
Traded in other countries:3A0.Germany,
Amyris Inc is a renewable products company engaged in providing sustainable alternatives to petroleum-sourced products. It developed microbial engineering and screening technologies that modify the way microorganisms process sugars.

Amyris Inc was incorporated in California on July 17, 2003 and reincorporated in Delaware on June 10, 2010. The Company is a renewable products company engaged in providing sustainable alternatives to petroleum-sourced products. It developed microbial engineering and screening technologies that modify the way microorganisms process sugars. The Company is engaged in developing various products to address five identified markets including cosmetics, lubricants, flavors and fragrances, performance materials, and transportation fuels. The Company is using its proprietary synthetic biology platform to design microbes, mainly yeast, and use them as living factories in established fermentation processes to convert plant-sourced sugars into renewable hydrocarbons. The Company is developing, and, in some cases, already commercializing, products from these hydrocarbons in several target markets, including cosmetics, lubricants, flavors and fragrances, performance materials, and transportation fuels. It calls these No Compromise products because it designs them to perform comparably to currently available products. The Company's first commercialization efforts have been focused on a renewable hydrocarbon molecule called farnesene Biofene, which forms the basis for various products varying from specialty chemical applications to transportation fuels, such as diesel. In addition, the Company has entered into various contract manufacturing agreements to support commercial production. The Company had 413 issued U.S. and foreign patents and 295 pending U.S. and foreign patent applications that are owned by or licensed to it. The Company is subject to a various federal, state, local and international laws, regulations and permit requirements governing the use, generation, manufacture, transportation, storage, handling and disposal of these materials in the United States, Brazil and other countries where it operates.

Ratios

vs
industry
vs
history
P/S 1.51
AMRS's P/S is ranked lower than
70% of the 1063 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.05 vs. AMRS: 1.51 )
Ranked among companies with meaningful P/S only.
AMRS' s P/S Range Over the Past 10 Years
Min: 0.52  Med: 3.84 Max: 9.58
Current: 1.51
0.52
9.58
Current Ratio 0.29
AMRS's Current Ratio is ranked lower than
97% of the 935 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.74 vs. AMRS: 0.29 )
Ranked among companies with meaningful Current Ratio only.
AMRS' s Current Ratio Range Over the Past 10 Years
Min: 0.29  Med: 1.45 Max: 11.36
Current: 0.29
0.29
11.36
Quick Ratio 0.21
AMRS's Quick Ratio is ranked lower than
97% of the 935 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.24 vs. AMRS: 0.21 )
Ranked among companies with meaningful Quick Ratio only.
AMRS' s Quick Ratio Range Over the Past 10 Years
Min: 0.21  Med: 1.34 Max: 11.22
Current: 0.21
0.21
11.22
Days Inventory 90.71
AMRS's Days Inventory is ranked lower than
70% of the 1013 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 66.82 vs. AMRS: 90.71 )
Ranked among companies with meaningful Days Inventory only.
AMRS' s Days Inventory Range Over the Past 10 Years
Min: 11.23  Med: 42.83 Max: 139.58
Current: 90.71
11.23
139.58
Days Sales Outstanding 58.80
AMRS's Days Sales Outstanding is ranked higher than
51% of the 856 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 59.33 vs. AMRS: 58.80 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMRS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.75  Med: 22.19 Max: 73.27
Current: 58.8
7.75
73.27
Days Payable 67.38
AMRS's Days Payable is ranked higher than
68% of the 903 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 47.70 vs. AMRS: 67.38 )
Ranked among companies with meaningful Days Payable only.
AMRS' s Days Payable Range Over the Past 10 Years
Min: 10.32  Med: 62.01 Max: 92.17
Current: 67.38
10.32
92.17

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.40
AMRS's Price/Median PS Value is ranked higher than
93% of the 1044 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 1.14 vs. AMRS: 0.40 )
Ranked among companies with meaningful Price/Median PS Value only.
AMRS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.41  Med: 1.10 Max: 2.52
Current: 0.4
0.41
2.52
Earnings Yield (Greenblatt) (%) -40.05
AMRS's Earnings Yield (Greenblatt) (%) is ranked lower than
97% of the 1103 Companies
in the Global Specialty Chemicals industry.

( Industry Median: 5.80 vs. AMRS: -40.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AMRS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -40.05  Med: 7.70 Max: 8.7
Current: -40.05
-40.05
8.7

More Statistics

Revenue (TTM) (Mil) $35.09
EPS (TTM) $ -1.51
Beta0.91
Short Percentage of Float7.28%
52-Week Range $0.36 - 2.62
Shares Outstanding (Mil)211.17
» More Articles for AMRS

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlights Jun 21 2016 
Insiders Top Buys: Amyris Inc. Aug 07 2015 
Weekly CEO Sells Highlight: Netlist Inc, LifePoint Hospitals Inc, Amyris Inc, and Sapient Corp. May 25 2014 
Billionaires Hold Waning Biotechs 42% Off Oct 16 2013 
Weekly CEO Sells Highlight: Amyris, AtriCure, 3D Systems Corporation and Cooper Tire & Rubber Compan Sep 10 2012 
Weekly CFO Sells Highlight: SCHW, TIBX, IL, AMRS, BCR, CCOI, CBST Apr 24 2011 
Weekly CEO Sells Highlight: MU, CRIS, HIL, and AMRS Apr 03 2011 

More From Other Websites
Weekly CEO Sells Highlights Jun 21 2016
AMYRIS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... Jun 20 2016
Demand for Aviation Biofuels Grows as Green Regulations Loom Jun 18 2016
Takasago and Amyris Begin Commercialization of Novel Fragrance Product Being Introduced at the 2016... Jun 14 2016
Takasago and Amyris Begin Commercialization of Novel Fragrance Product Being Introduced at the 2016... Jun 14 2016
Amyris Fuels First Delivery of New Airbus A350-900 Airplane for Cathay Pacific as Part of Two-Year... Jun 13 2016
Amyris Fuels First Delivery of New Airbus A350-900 Airplane for Cathay Pacific as Part of Two-Year... Jun 13 2016
Amyris Announces Collaboration with Johnson & Johnson Innovation for Biosynthetic Drug Discovery Jun 06 2016
Amyris to Participate in June 2016 Investor Conferences Jun 06 2016
Amyris Announces Collaboration with Johnson & Johnson Innovation for Biosynthetic Drug Discovery Jun 06 2016
Gen9 and Amyris Announce Supply Agreement for Synthetic DNA Jun 02 2016
AMYRIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers May 31 2016
Amyris to Participate in June 2016 Investor Conferences May 27 2016
7 Stocks Under $10 to Trade for Big Profits May 27 2016
Amyris & CJ CheilJedang Corporation Creating Manufacturing and Sales Partnership May 20 2016
Amyris to Participate in Upcoming Investor Conferences in May 2016 May 20 2016
Amyris & CJ CheilJedang Corporation Creating Manufacturing and Sales Partnership May 20 2016
AMYRIS, INC. Financials May 19 2016
ETF’s with exposure to Amyris, Inc. : May 19, 2016 May 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)